ライフサイエンスコーパス: bladder

1 he esophagus, stomach, colon, uterus and the bladder.

2 riven by catheter infusion of fluid into the bladder.

3 is than urothelial carcinomas of the urinary bladder.

4 pproved only for the treatment of overactive bladder.

5 rgans: heart, skeletal muscle, intestine and bladder.

6 ating that vaginal colonization can seed the bladder.

7 d and neck, oesophagus, stomach, cervix, and bladder.

8 TRPV4 up-regulation in aging and overactive bladders.

9 s not found to accumulate in nontumor murine bladders.

10 r to other kidney transplantations on native bladders.

11 examined adaptive immune responses in mouse bladders.

12 c (1.36, 1.03-1.79), lung (2.21, 1.44-3.39), bladder (2.86, 1.47-5.55), and laryngeal (2.53, 1.21-5.2

13 Genes were chosen for assay (32 for bladder; 48 for colon) based on their established role i

14 thotopically sutured to the recipient, whose bladder above the ureteral opening level was removed.

15 at both compounds are BBB permeable and that bladder accumulation is low until at least 5 min post in

16 erents (from NG, TL, and LS ganglia) and 128 bladder afferents (from TL and LS ganglia) were analyzed

17 Furthermore, colon and bladder afferents expressed genes at similar levels, alt

18 Profiling of TL and LS bladder afferents was also performed.

19 There were clusters of colon and bladder afferents, defined by mRNA profiling, that local

20 iral defense is a driving force in cervical, bladder and head-and-neck carcinoma.

21 antithrombotics and for treating hyperactive bladder and inflammation.

22 ous Ca(2+) sparks and BK channel activity in bladder and urethra SMCs.

23 signaling in Mcoln1 (-/-) mice rendered both bladder and urethra smooth muscle hypercontractile.

24 (2+)-signaling activity and contractility in bladder and urethral smooth muscle cells (SMCs).

25 cterized by an anomalous opening between the bladder and/or rectum and vagina resulting in continuous

26 ns with untapped opportunities (e.g., sinus, bladder, and colon).

27 carcinogen known to target the skin, lungs, bladder, and digestive organs, but its role as a primary

28 Bladder/body mass ratios with PBO increased significantl

29 older with one of 12 types of solid tumours (bladder, breast, colon, endometrial, laryngeal, lung, me

30 Because the evidence of association with bladder cancer (BC) is limited, we aimed to assess assoc

31 Invasive bladder cancer (BC) is one of the most lethal malignant

32 protein, is overexpressed in people who have bladder cancer (BC).

33 rbohydrate-binding proteins overexpressed in bladder cancer (BCa) cells.

34 nuclear androgen receptor (nAR) to increase bladder cancer (BCa) progression, the impact of androgen

35 Advanced Bladder Cancer (BLCA) remains a clinical challenge that

36 C1) activated kinase 4 (PAK4) in a subset of Bladder cancer (BLCA).

37 High-grade nonmuscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease.

38 Muscle-invasive bladder cancer (MIBC) is a heterogeneous disease that of

39 nt predictors of survival in muscle-invasive bladder cancer (MIBC).

40 le invasive (HGT1) micropapillary variant of bladder cancer (MPBC).

41 s received mBCG, four had nonmuscle invasive bladder cancer (NMIBC) after induction, three had NMIBC

42 ses correlating to the basal centroid of the bladder cancer analysis of subtypes by gene expression 4

43 thelial carcinoma is the most common type of bladder cancer and accounts for 90% of bladder cancer ca

44 r, with BCG-unresponsive non-muscle-invasive bladder cancer and an Eastern Cooperative Oncology Group

45 post treatment surveillance in patients with bladder cancer and cancer detection in patients with sus

46 s have been shown to cure some patients with bladder cancer and significantly decrease adverse events

47 mechanisms of FOXA1 and PTEN inactivation in bladder cancer and their contribution to tumor heterogen

48 tion of BCG-unresponsive non-muscle-invasive bladder cancer and were therefore excluded from efficacy

49 -fixed paraffin-embedded (FFPE) tissue using bladder cancer as an exemplar; and (2) examine the influ

50 e in order to estimate odds ratios (ORs) for bladder cancer associated with the mean THM level in eac

51 ction for average residential THM levels and bladder cancer by pooling data from studies included in

52 mic profiling studies have demonstrated that bladder cancer can be divided into two molecular subtype

53 % CI: 1,522, 4,060; 43%) annual attributable bladder cancer cases could potentially be avoided.

54 e fraction (PAF), and number of attributable bladder cancer cases in different scenarios using incide

55 pe of bladder cancer and accounts for 90% of bladder cancer cases in the USA and Europe.

56 accounting for 6,561 (95% CI: 3,389, 9,537) bladder cancer cases per year.

57 tients and analysis of distinct melanoma and bladder cancer cell lines suggested differences in cance

58 addition, FOXA1 is hypermethylated in basal bladder cancer cell lines, and this is reversed by treat

59 ch achieves highly specific capture rates of bladder cancer cells based on their Epithelial Cell Adhe

60 gger AMPK-dependent autophagic cell death in bladder cancer cells by PI3K/AKT/HIF-1alpha-mediated gly

61 K2 significantly promoted the glycolysis in bladder cancer cells by upregulating glucose consumption

62 The pronounced glycocalyx of bladder cancer cells enhanced the internalisation of nan

63 oundly abrogated AMPK activation and rescued bladder cancer cells from Vitamin K2-triggered autophagi

64 ar gammadelta T-cell-mediated eradication of bladder cancer cells in vitro.

65 hole cell immunocapture technology to detect bladder cancer cells shed in patient urine ex vivo.

66 In the present study, we found CNF1 induced bladder cancer cells to secrete vascular endothelial gro

67 as well as whole transcriptome sequencing of bladder cancer cells {plus minus} tet-on ZFP36L1 was per

68 Using bladder cancer cells, we confirmed the role of PAK4 in B

69 tive and migratory and invasive abilities in bladder cancer cells.

70 3K/AKT and HIF-1alpha-mediated glycolysis in bladder cancer cells.

71 e and provides an important resource for the bladder cancer community.

72 ) are typically extrapolated from studies of bladder cancer despite their distinct clinical and molec

73 o found positively correlated with the human bladder cancer development.

74 ltiple microbiopsies from five patients with bladder cancer enabled comparisons with cancer-free indi

75 inal cells in mice results in development of bladder cancer exhibiting squamous features as well as e

76 ereas mutations were absent in several major bladder cancer genes.

77 ing of the molecular biology and genetics of bladder cancer has evolved the way localized and advance

78 Sequencing of bladder cancer has revealed that loss-of-function mutati

79 The field of research in bladder cancer has seen significant advances in recent y

80 n order to facilitate molecular subtyping of bladder cancer in primary care centers, we analyzed the

81 tool for assessment of molecular subtypes of bladder cancer in routine clinical practice.

82 investigating intracellular heterogeneity of bladder cancer invasion and analyzing patient derived sa

83 mbly approach for recapitulating features of bladder cancer invasion in 3D microenvironments and prob

84 The involvement of DLL4 expressing cells in bladder cancer invasion was also observed in patient sam

85 provide a physiological context for studying bladder cancer invasion within 3D microenvironments and

86 role of NOTCH1-DLL4 signaling in collective bladder cancer invasion.

87 Intratumoral heterogeneity in bladder cancer is a barrier to accurate molecular sub-cl

88 Bladder cancer is a common malignancy in women and is th

89 Bladder cancer is an increasingly common malignancy, and

90 ingly common malignancy, and muscle invasive bladder cancer is associated with particularly high rate

91 Bladder cancer is common and has one of the highest recu

92 nificant therapeutic impact on patients with bladder cancer is found in the use of immune checkpoint

93 High-grade T1 (HGT1) bladder cancer is the highest risk subtype of non-muscle

94 llus Calmette-Guerin (BCG) immunotherapy for bladder cancer is the only bacterial cancer therapy appr

95 Bladder cancer is the tenth most common cancer type worl

96 1) is a key UPEC toxin; however, its role in bladder cancer is unknown.

97 irmation but suggest that management of HGT1 bladder cancer may be improved via molecular characteriz

98 ), leading to subsequent angiogenesis in the bladder cancer microenvironment.

99 genes frequently affected in muscle-invasive bladder cancer of nonpapillary origin, focusing on poten

100 Although advanced bladder cancer overall has a poor prognosis, a subset of

101 The estimated bladder cancer PAF was 4.9% [95% confidence interval (CI

102 can origin, and decreased immune activity in bladder cancer patients of East Asian origin.

103 edicts a clinical response in 244 metastatic bladder cancer patients treated with anti-PD-L1.

104 formed multi-omic profiling of the kinome in bladder cancer patients with the goal of identify therap

105 iagnostic tool, we analyzed the plasma of 20-bladder cancer patients without any sample processing st

106 y in cell lines and primary tumor cells from bladder cancer patients.

107 ated with poor survival in liver, colon, and bladder cancer patients.

108 t SCCB shares a urothelial origin with other bladder cancer phenotypes by showing that urothelial cel

109 lecular similarities and differences between bladder cancer phenotypes.

110 The morphologic and molecular diversity of bladder cancer poses significant challenges in elucidati

111 Bladder cancer prognosis is closely linked to the underl

112 mechanism through which UPEC contributes to bladder cancer progression, and may provide potential th

113 lectively, LAT1 significantly contributed to bladder cancer progression.

114 e most suitable endogenous control genes for bladder cancer qPCR.

115 Bladder cancer ranges from unaggressive and usually noni

116 been consistently associated with increased bladder cancer risk.

117 still could lead to a considerable burden of bladder cancer that could potentially be avoided by opti

118 analysis of histone modifications in primary bladder cancer tissue and provides an important resource

119 may represent a novel therapeutic option in bladder cancer treatment.

120 expression signature was identified between bladder cancer tumor blood vasculature with tumor blood

121 e which identified the molecular subtypes of bladder cancer with 80-94% sensitivity and 83-93% specif

122 highest risk subtype of non-muscle-invasive bladder cancer with unpredictable outcome and poorly und

123 GF expression, and angiogenesis in the human bladder cancer xenografts.

124 howing promising results in the treatment of bladder cancer, including infigratinib and pemigatinib,

125 termediate and high-risk non-muscle-invasive bladder cancer, the therapeutic options for muscle-invas

126 s that are expressed differentially in human bladder cancer-associated blood vessels to find novel bi

127 ing has identified the genes most mutated in bladder cancer.

128 iated with adverse reproductive outcomes and bladder cancer.

129 apy for BCG-unresponsive non-muscle-invasive bladder cancer.

130 ssion profile and functional role of LAT1 in bladder cancer.

131 as in the peripheral blood of patients with bladder cancer.

132 nce of carcinoma in situ, and prior low-risk bladder cancer.

133 ay provide potential therapeutic targets for bladder cancer.

134 egarding the classification and treatment of bladder cancer.

135 focusing on 95 genes known to be mutated in bladder cancer.

136 a specific inhibitor of LAT1, was studied in bladder cancer.

137 fectors YAP and TAZ is frequently altered in bladder cancer.

138 ve therapy for high-risk non-muscle-invasive bladder cancer.

139 cancer detection in patients with suspected bladder cancer.

140 ratumoral heterogeneity in immune markers in bladder cancer.

141 l autoimmunity and anti-PD-L1 monotherapy in bladder cancer.

142 ure and estimated the attributable burden of bladder cancer.

143 tested for the treatment of FGFR-rearranged bladder cancer.

144 ced melanoma, non-small cell lung cancer, or bladder cancer.

145 der (SCCB) is a rare and lethal phenotype of bladder cancer.

146 -1 immunotherapy occur but are infrequent in bladder cancer.

147 ts with BCG-unresponsive non-muscle-invasive bladder cancer.

148 ts with BCG-unresponsive non-muscle-invasive bladder cancer.

149 e kinase (RTK) signaling frequently occur in bladder cancer.

150 ingle gene expression signatures to classify bladder cancers into distinct subtypes.

151 Breast cancers, bladder cancers, and uterine cancers have spatial patter

152 enes encoding cohesin subunits are common in bladder cancers, paediatric sarcomas, leukaemias, brain

153 cascade components that are up-regulated in bladder cancers.

154 infections, is associated with prostate and bladder cancers.

155 the precursor lesion of most muscle-invasive bladder cancers.

156 le subjects exhibited a significantly larger bladder capacity and compliance compared to females.

157 Deltapressure was greatest with propofol, bladder capacity was highest with alpha-chloralose, non-

158 s, the epithelium was markedly thickened and bladder capacity was reduced relative to controls.

159 and propofol) on urodynamic (Deltapressure, bladder capacity, bladder compliance, non-voiding contra

160 eased peak voiding pressure, voiding volume, bladder capacity, residual volume, and number of non-voi

161 by which urogenital schistosomiasis promotes bladder carcinogenesis.

162 lung carcinoma (seven patients, 15.6%), and bladder carcinoma (four patients, 8.9%).

163 tumor blood vasculature from human invasive bladder carcinoma (I-BLCA) and normal bladder tissue vas

164 in plasma was also observed in non-invasive bladder carcinoma and I-BLCA.

165 mCD40L versus soluble CD40L (sCD40L) on T24 bladder carcinoma gene expression profiling.

166 Muscle-invasive bladder carcinomas (MIBCs) are aggressive genitourinary

167 ns such as swallowing assessments, bowel and bladder care, mobility assessments, and consistent secon

168 ing of bacterial reservoirs harboured within bladder cells compared with unencapsulated drug.

169 ance of luminal and basal gene expression in bladder cells.

170 mediated increase in the colony formation of bladder cells.

171 urodynamic (Deltapressure, bladder capacity, bladder compliance, non-voiding contractions, bladder pr

172 on has been detected in various pathological bladder conditions.

173 mice lacking functional PIEZO2 have impaired bladder control, and humans lacking functional PIEZO2 re

174 In SCI + PBS rat bladders, cystometry showed increased peak voiding press

175 ies, we present 3 cases, 2 enterically and 1 bladder-derived SPK transplant patients, with anastomoti

176 tations in UTX and FGFR3 converge to disrupt bladder differentiation programs that could serve as a t

177 sed to understand bladder function, diagnose bladder disease, and develop treatments for dysfunctions

178 SM contractility associated with obstructive bladder disease.

179 y result from urinary tract malformations or bladder disturbances.

180 In the Cox regression analysis, bladder drained pancreas was associated with lower proba

181 al therapy for obstruction-induced myopathic bladder dysfunction (from benign prostatic hyperplasia o

182 Thus, recurrence of UTIs and associated bladder dysfunction are the outcome of the preferential

183 Bladder dysfunction is a common clinical problem attribu

184 Bladder dysfunction is associated with the overexpressio

185 candidate of possible surgical solution for bladder dysfunction, we propose a novel orthotropic mous

186 ts might be effective drugs for treatment of bladder dysfunction.

187 V4 may be a promising therapeutic target for bladder dysfunctions.

188 ieved in all cells in 2D cultures of a human bladder epithelial progenitor cell line in a dose-depend

189 The bladder epithelial repair response is cumulative and abe

190 L(+) dendritic cells, which migrate into the bladder epithelium after infection before trafficking to

191 lure of infused antibiotics to penetrate the bladder epithelium and accumulate to high enough levels

192 ivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for

193 Overactive bladders exhibited greater TRPV4-induced ATP release wit

194 = 21), central neurogenic bladder (n = 13), bladder exstrophy (n = 14), prune belly syndrome (n = 12

195 ves, neurogenic bladder, ureteral ectopy, or bladder exstrophy.

196 alid paradigm to study the brain response to bladder filling by (1) filling the bladder naturally wit

197 lates afferent nerve activity in response to bladder filling during the urination cycle.

198 r-activated bladder pressure from the end of bladder filling to peak pressure in the male subjects.

199 s lacking functional PIEZO2 report deficient bladder-filling sensation.

200 into proximal and distal regions of colon or bladder, followed by single-cell qRT-PCR and analysis vi

201 c fluid stem cell (hAFSC) transplantation on bladder function and molecular changes in spinal cord-in

202 Urodynamic studies, used to understand bladder function, diagnose bladder disease, and develop

203 bladder transplant is able to provide normal bladder function.

204 mptomatic bacteriuria the focus should be on bladder function.

205 icle; liver; spleen; kidneys; bowel; urinary bladder; gluteus muscle; and malignant lesions.

206 Readouts included bladder histology and ex vivo assessments of urothelial

207 undice is rare in KD without associated gall bladder hydrops and tends to occur in older patients.

208 ) typically evoke prompt and vigorous innate bladder immune responses, including extensive exfoliatio

209 Swim bladders in sciaenid fishes function in hearing in some

210 s that connect the sonic muscles to the swim bladder) in this and other sciaenids.

211 associated with asymptomatic bacteriuria or bladder infection (cystitis).

212 We found that, following each bladder infection, a highly T helper type 2 (T(H)2)-skew

213 roperoxidase and deiodinase to impaired swim bladder inflation in fish has recently been developed.

214 key event relationship linking impaired swim bladder inflation to TH disruption.

215 ctor (KGF) improves cyclophosphamide-induced bladder injury.

216 Direct bladder instillation of antibiotics has proved disappoin

217 ction as Helmholz absorbers turning the swim bladder into a high-pass filter responsible for the abse

218 Metastatic urothelial carcinoma of the bladder is generally incurable by current chemotherapy a

219 Lymphoepithelioma-like carcinoma of the bladder (LELC-B) is a rare subtype of urothelial carcino

220 The source organs consisted of the kidneys, bladder, liver, heart, spleen, bone marrow, uterus, and

221 We sequenced 2097 bladder microbiopsies from 20 individuals using targeted

222 Human bladder mucosa presented similarities to guinea pigs.

223 ally relevant treatment phase of obstructive bladder myopathy.

224 ), spina bifida (n = 21), central neurogenic bladder (n = 13), bladder exstrophy (n = 14), prune bell

225 sponse to bladder filling by (1) filling the bladder naturally with oral water ingestion, (2) examini

226 hospitalizations in subjects with neurogenic bladder (NB) due to spinal cord injury (SCI).

227 Overactive bladder (OAB) is a highly prevalent symptom complex char

228 esponse to UPEC infection was evident in the bladder of the same animals.

229 .55; 95% CI 1.27-1.88; p = 1.24 x 10-5), and bladder (OR 1.40; 95% CI 1.92-2.65; p = 9.40 x 10-5) and

230 esity-associated SPCs, such as lung, urinary bladder, oral cavity/pharynx, colorectal, pancreatic, ut

231 cells through multiple layers of a 3D human bladder organoid model causing minimal cell toxicity, di

232 l lines derived not only from PDAC, but also bladder, ovarian, gastric, lung, and basal-like breast c

233 Voiding activity analyses revealed bladder overactivity in Mcoln1 (-/-) mice.

234 eumoniae is a respiratory, blood, liver, and bladder pathogen of significant clinical concern.

235 The bladder pathology of urogenital schistosomiasis is cause

236 -/-) ) induces a hyperdistended/hypertrophic bladder phenotype.

237 Conversely, many are suitable for bladder preservation and may maintain their prediagnosis

238 Given the need for alternative bladder-preserving therapies, we identified genomic alte

239 nd that the recipient mice displayed similar bladder pressure and urine secretion ability compared to

240 e flow studies showed a significantly higher bladder pressure at voiding onset, peak pressure, and el

241 ressure, and elevation in detrusor-activated bladder pressure from the end of bladder filling to peak

242 Propofol and dexmedetomidine had the highest bladder pressure slopes during the initial and final por

243 ladder compliance, non-voiding contractions, bladder pressure slopes) and anesthetic (change in heart

244 in (e.g. that of cornea, oesophagus, vagina, bladder, prostate) that express the transcription factor

245 within approximately 20% of in vivo urinary bladder radiotracer concentrations.

246 analyzed SPECT/CT images for in vivo urinary bladder radiotracer uptake using quantitative software.

247 imary prostate cancer; however, the tumor-to-bladder ratio was significantly higher with (18)F-rhPSMA

248 2 (T(H)2)-skewed immune response directed at bladder re-epithelialization is observed, with limited c

249 The present results showed that SCI bladders released IGF-1 and TGF-beta1 to stimulate elast

250 c mutation and clonal selection in the human bladder remains unknown.

251 ay be confounded by artificially filling the bladder repeatedly at a high rate and examining associat

252 and a fistula between the appendix, urinary bladder, right scrotum, and right groin.

253 ly 350 mL of water, and had a 10 min "fuller bladder" rs-fMRI scan approximately 1 h later.

254 A second 10 min "empty bladder" rs-fMRI scan was conducted immediately followin

255 Small cell carcinoma of the bladder (SCCB) is a rare and lethal phenotype of bladder

256 hat the majority of LELs in freshly isolated bladder SMCs were essentially immobile.

257 ls with ryanodine type 2 receptors (RyR2) in bladder SMCs.

258 ) proteins desmin and vimentin in obstructed bladder smooth muscle (BSM).

259 As rapamycin can attenuate bladder smooth muscle hypertrophy and dysfunction during

260 in guinea-pig urothelium, suburothelium, and bladder smooth muscle, with urothelial predominance.

261 eatures as well as enhanced sensitivity to a bladder-specific carcinogen.

262 ted by peripheral mechanical stimuli such as bladder stretch and urethral flow(4).

263 sues, where it is required for low-threshold bladder-stretch sensing and urethral micturition reflexe

264 Similarity of bladder structure between recipient and control mice was

265 kground organ SUV(mean)) using muscle (T/M), bladder (T/B), and intestine (T/I) as background organs

266 vasive bladder carcinoma (I-BLCA) and normal bladder tissue vasculature was compared using differenti

267 tions (UTIs), which commonly ascend from the bladder to the kidney, is a growing concern because it p

268 These results indicate that the mouse bladder transplant is able to provide normal bladder fun

269 nction, we propose a novel orthotropic mouse bladder transplantation model.

270 In the urinary bladder, TRPV4 is not only abundantly expressed in the u

271 Herein we show that BCG-induced bladder tumor elimination requires CD4 and CD8 T cells,

272 T cells from human bladder tumors and non-malignant tissue were assessed wi

273 Bladder tumors can present with gross or microscopic hem

274 Detailed genetic analyses of HGT1 bladder tumors identify features that correlate with out

275 for PET imaging of galectin-1-overexpressing bladder tumors.

276 nts that commonly cooccur in muscle invasive bladder tumors.

277 istone methylation patterns of human primary bladder tumours by chromatin immunoprecipitations and ne

278 In urothelial carcinoma of the bladder (UCB), silencing of GULP1 facilitated the nuclea

279 uch as posterior urethral valves, neurogenic bladder, ureteral ectopy, or bladder exstrophy.

280 ay cause hemorrhagic cystitis and eventually bladder urothelial cancer.

281 how that PIEZO2 acts as a sensor in both the bladder urothelium and innervating sensory neurons.

282 The newly recognized sensory role of bladder urothelium has generated intense interest in ide

283 Sciaenid swim bladders vary from simple carrot-shaped to two-chambered

284 /MBq for an adult male, with a 1.5-h urinary bladder voiding interval.

285 the highest absorbed doses were the urinary bladder wall (0.38 mSv/MBq) and kidneys (0.054 mSv/MBq).

286 organs with the highest effective doses were bladder wall (2.41E-03 mSv/MBq), followed by ovaries (1.

287 No injury was found on the bladder wall or intervening tissue.

288 -beta1 to stimulate elastin and collagen for bladder wall remodelling, and hAFSC transplantation impr

289 , fluid accumulation, pleural effusion, gall-bladder wall thickening and rapid haematocrit rise concu

290 by immune responses to eggs deposited in the bladder wall.

291 e neurovascular bundles, the rectum, and the bladder wall.

292 the intensity of granulomatous responses to bladder-wall-injected S. haematobium eggs in Il4ra(-/-)

293 urogenital schistosomiasis by injecting the bladder walls of IL-4 receptor-alpha knockout (Il4ra(-/-

294 ion of the anterior chamber (AC) of the swim bladder were available.

295 Female Sprague-Dawley rat bladders were partially obstructed (PBO) by suturing aro

296 Bladders were weighed and processed for a high-throughpu

297 c accumulation of radiotracer in the urinary bladder which may cause some lesions in its vicinity to

298 d resembles a kidney, connected to a urinary bladder with a nephropore (exit opening) and a complex o

299 es Boesemania microlepis has an unusual swim bladder with a slightly restricted anterior region and 6

300 The donor bladder with abdominal aorta and inferior vena cava was